Healthcare Global Enterprises Limited has informed the Exchange regarding a press release dated August 01, 2025, titled "Q1 FY26 Financial & Business Update".
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG, India's largest cancer care provider, reported Q1 FY26 revenue of Rs. 6,132 Mn, up 17% year-on-year, driven by strong performance across key cities including Ahmedabad, Kolkata, Nagpur, and Mumbai. Established centers grew 16% to Rs. 5,396 Mn while emerging centers surged 24% to Rs. 587 Mn. Adjusted EBITDA rose 20% to Rs. 1,118 Mn with margin expanding to 18.2% from 17.7%, helped by operating leverage and cost efficiencies. However, profit after tax (PAT) dropped 61% to Rs. 47 Mn due to higher depreciation and interest costs from recent growth investments and acquisitions. OPD footfalls grew 17% and bed occupancy improved to 62% from 61%. The company also appointed Dr. Manish Mattoo as the new Executive Director and CEO.
Investors will likely focus on the sharp PAT decline despite healthy revenue and EBITDA growth, which signals that near-term profitability is being weighed down by expansion costs. Margin expansion and strong operational metrics are positives, but higher depreciation and interest from recent investments will continue to pressure bottom-line growth in the short term.